Editas Medicine, Inc. (NASDAQ:EDIT) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - Head, Corporate Communications & IR Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Thanks for joining us today for a fireside chat with Editas. My name is Liisa Bayko. I'm a biotech analyst at Evercore ISI, and I'm joined by the team here at Editas. So I'll just turn over. You can do some brief introductions and we'll the ...

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2023 Healthcare Conference November 14, 2023 1:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha Okay, let's go ahead and get started with the next session. Thanks everyone for joining us. For the next half hour or so, we're going to be talking Editas Medicine. My name is Dae Gon Ha, biotech analyst at Stifel. Joining me here on stage, we have Erick ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial & Strategy Officer Conference Call Participants Brian Cheng - J.P. Morgan Samantha Semenkow - Citi Joon Lee - Truist Securities Greg Harrison - Bank of America Gena Wang - Barclays Jack Allen - Baird Dae Gon Ha - Stifel Phil Nadeau - T ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 ______________ ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_2481022083899b1fd07c6210bb763944.html ...

Summary of Editas Medicine, Inc. Conference Call Company Overview - **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) - **Date**: September 11, 2023 - **Participants**: - Gilmore O'Neill - President and CEO - Baisong Mei - Senior Vice President and Chief Medical Officer - Terence Flynn - Morgan Stanley Analyst Key Points Industry and Company Strategy - Editas has focused on executing its revised strategy, which includes terminating or divesting certain assets, notably the NK oncology asset to Shoreline, which has been a successful collaboration [5][6] - The company has redirected resources towards its EDIT-301 therapy for hemoglobinopathies, achieving a significant milestone by enrolling 20 patients in the RUBY study by the end of May [6][10] - A strategic refocus led to a 20% reduction in headcount, targeting capabilities that were no longer necessary [8] Clinical Development and Pipeline - The company reported robust results from its sickle cell program, with patients demonstrating significant increases in fetal hemoglobin levels and correction of anemia [9][28] - Editas raised $117 million, extending its cash runway into Q3 2025, which is crucial for the ongoing clinical studies [10] - The FDA accepted the BLA filing for exa-cel, which includes data from 17 patients, validating the company's hypothesis regarding the efficacy cohort [6][10] Differentiation and Technology - Editas emphasizes its proprietary AsCas12a CRISPR enzyme, which is believed to be more efficient and specific than Cas9, reducing off-target effects [12][13] - The company is pivoting towards in vivo applications and is actively seeking external technologies to complement its capabilities, particularly in non-viral delivery methods [19][20] Future Directions and Market Position - Editas is interested in targeting hematopoietic stem cells and believes that its approach will significantly impact the treatment of sickle cell disease [17] - The company anticipates a growing patient population eligible for its therapies, estimating between 20,000 to 35,000 patients in the U.S. alone [39] - Editas views the upcoming approvals of competing products as an opportunity to demonstrate the safety and efficacy of its own therapies [34][35] Intellectual Property and Licensing - Editas plans to monetize its IP portfolio, focusing on sublicensing its Cas12 and Cas9 technologies to developers [49] - The company has foundational IP from Broad, Harvard, and MIT, which is expected to be valuable for programs nearing approval [49] Upcoming Milestones - Editas is preparing for data updates by the end of the year, potentially at the ASH conference, with expectations of presenting longer follow-up data on existing patients [31][32] - The company is optimistic about its ability to recruit patients and manage site capacity for commercial launch, drawing parallels to the CAR-T space [43][47] Regulatory Environment - Editas does not foresee a higher bar from the FDA due to the approval of competing products, viewing it instead as an opportunity to showcase its differentiated approach [34][35] - The upcoming Advisory Committee meeting is expected to focus on the safety and efficacy of CRISPR technology, with Editas anticipating a positive outcome [41][42] Conclusion Editas Medicine is strategically positioning itself in the genetic medicine landscape with a focus on its proprietary CRISPR technology and a robust clinical pipeline. The company is optimistic about its future prospects, driven by recent funding, promising clinical results, and a clear strategy for differentiation in a competitive market.

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_ff79b632a4c1c83306ce6e7db9126fb9.html ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Samantha Semenkow - Citi Greg Harrison - Bank of America Joon Lee - Truist Securities Gena Wang - Barclays Dae Gon Ha - Stifel Yanan Zhu - Wells Fargo Rick ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delawa ...

Editas Medicine, Inc. (NASDAQ:EDIT) EDIT-301 Clinical Update Conference Call June 12, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Phil Nadeau - Cowen & Company Jacques Villefranc - Stifel Lisa Walter - RBC Capital Markets Jay Olson - Oppenheimer Yanan Zhu - Wells Fargo Madhu Kumar ...